{
    "clinical_study": {
        "@rank": "161577", 
        "acronym": "RESCIND-STEMI", 
        "arm_group": [
            {
                "arm_group_label": "Guideline Hydration", 
                "arm_group_type": "Active Comparator", 
                "description": "No hydration for patients without chronic kidney disease(CrCl<60ml/min),or Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride) after diagnosis of chronic kidney disease until 24 hours after PCI. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or Killip\u2161/\u2162."
            }, 
            {
                "arm_group_label": "Adequate Hydration", 
                "arm_group_type": "Active Comparator", 
                "description": "Receiving hydration with a 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride) from randomization to the end of the procedure, the measurement of LVEDP was conducted after the procedure, a sliding-scale hydration was employed in the LVEDP-guided hydration arm that was based on LVEDP for 2 hours: 5 ml/kg/hr for LVEDP <13 mmHg, 3 ml/kg/hr for LVEDP 13-18 mmHg, and >1.5 ml/kg/hr for LVEDP >18 mmHg, whereas,0.5 ml/kg/hr for LVEDP >20 mmHg, continue hydration with a 1 mL/kg until 24 hours after procedure. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or Killip\u2161/\u2162."
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the efficacy of 2 different hydration strategies, hydration according to clinical\n      guideline and adequate hydration, on contrast-induced nephropathy in patients with STEMI\n      undergoing primary PCI to investigate the possible beneficial role of periprocedural\n      adequate hydration."
        }, 
        "brief_title": "Adequate Hydration for Prevention of Contrast-Induced Nephropathy After Primary Percutaneous Coronary Intervention", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "ST Elevation Myocardial Infarction", 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Kidney Diseases", 
                "Myocardial Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "all consecutive patients with STEMI\uff0cage at least 18 years, who were candidates for primary\n      PCI at our institution were considered for enrollment in the present study. Initial\n      exclusion criteria were contrast medium administration within the previous 14 days,\n      end-stage renal failure requiring dialysis, and refusal to give informed consent. Eligible\n      patients were randomly assigned in a 1:1 ratio to receive preprocedure and postprocedure\n      hydration (adequate hydration group), hydration according to clinical guideline (guideline\n      hydration group\uff0ccontrol group )"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  all consecutive patients with STEMI, age at least 18 years, who were candidates for\n             primary PCI were considered for enrollment.\n\n        Exclusion Criteria:\n\n          -  contrast medium administration within the previous 14 days or follow 72 hours,\n\n          -  end-stage renal failure or renal transplantation, and refuse PCI or dead during the\n             procedure,\n\n          -  heart failure of cardiac shock or New York Heart Association class IV,\n\n          -  recent acute kidney injury defined as an absolute increase of 0.5 mg/dl in serum\n             creatinine over baseline in the past 24h\n\n          -  ,the presence of lactation, pregnancy,\n\n          -  malignant tumour or life expectancy less than 1 year,\n\n          -  allergy to contrast, peri-procedural receipt of metformin\n             non\uff0dsteroidalanti\uff0dinflammatory drugs in the past 48h and during the study period,\n\n          -  planned renal carthterization or heart valvular surgery\u3002"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02067195", 
            "org_study_id": "CSC20140222"
        }, 
        "intervention": [
            {
                "arm_group_label": "Guideline Hydration", 
                "description": "No hydration for patients without chronic kidney disease(CrCl<60ml/min),or Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride) after diagnosis of chronic kidney disease until 24 hours after PCI. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or Killip\u2161/\u2162.", 
                "intervention_name": "Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride)", 
                "intervention_type": "Drug", 
                "other_name": "Guideline Hydration"
            }, 
            {
                "arm_group_label": "Adequate Hydration", 
                "description": "Receiving hydration with a 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride) from randomization to the end of the procedure, the measurement of LVEDP was conducted after the procedure, a sliding-scale hydration was employed in the LVEDP-guided hydration arm that was based on LVEDP for 2 hours: 5 ml/kg/hr for LVEDP <13 mmHg, 3 ml/kg/hr for LVEDP 13-18 mmHg, and >1.5 ml/kg/hr for LVEDP >18 mmHg, whereas,0.5 ml/kg/hr for LVEDP >20 mmHg, continue hydration with a 1 mL/kg until 24 hours after procedure. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or Killip\u2161/\u2162.", 
                "intervention_name": "3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride)", 
                "intervention_type": "Drug", 
                "other_name": "Adequate Hydration"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "acute myocardial infarction,contrast,coronary intervention", 
        "lastchanged_date": "February 19, 2014", 
        "location": {
            "contact": {
                "email": "liuyongyisheng@126.com", 
                "last_name": "Yong Liu, MD", 
                "phone": "86-20-83827812", 
                "phone_ext": "10528"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "501080"
                }, 
                "name": "Guangdong General Hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Adequate Hydration for Prevention of Contrast-Induced Nephropathy After Primary Percutaneous Coronary Intervention, A Randomized, Controlled Trial REduction of riSk of Contrast-Induced Nephropathy After carDiac Catheterization -ST-Elevation Myocardial Infarction", 
        "overall_contact": {
            "email": "chenjiyandr@126.com", 
            "last_name": "Jiyan Chen, MD", 
            "phone": "86-20-83827812", 
            "phone_ext": "10528"
        }, 
        "overall_official": [
            {
                "affiliation": "Guangdong Cardiovascular Institute,Guangdong General Hospital", 
                "last_name": "Jiyan Chen, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Guangdong Cardiovascular Institute,Guangdong General Hospital", 
                "last_name": "Yong Liu, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "defined as a greater than 25% or an absolute increase of 0.5 mg/dl in serum creatinine over baseline during the first 48- 72 h post-procedure", 
            "measure": "Contrast-Induced Nephropathy", 
            "safety_issue": "No", 
            "time_frame": "72 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02067195"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Guangdong General Hospital", 
            "investigator_full_name": "Jiyan Chen", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "defined as a greater than 50% or an absolute increase of 0.3 mg/dl in serum creatinine over baseline during the first 48h post-procedure", 
                "measure": "contrast-induced acute kidney injury", 
                "safety_issue": "No", 
                "time_frame": "48 hours"
            }, 
            {
                "description": "Defined as an absolute increase of 0.3 mg/dl in serum creatinine over baseline during the first 48h post-procedure and as a greater than 10% in Cystatin C  over baseline during the first 24h post-procedure", 
                "measure": "Composite contrast-induced acute kidney injury", 
                "safety_issue": "No", 
                "time_frame": "48 hours"
            }, 
            {
                "description": "Defined as a residual impairment of renal function indicated by a reduction of creatinine clearance more than 25% at 3 months in comparison with baseline", 
                "measure": "Persistent renal damage", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "defined as the alteration of creatinine clearance and estimated glomerular filtration rate (GFR) by using Cystatin C over baseline during the first 48- 72 h post-procedure", 
                "measure": "Alteration of renal fuction", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "description": "Including contrast-induced nephropathy requiring renal replacement therapy and death caused by contrast-induced nephropathy", 
                "measure": "Severe adverse renal events", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Major adverse cardiovascular events included death, re- current myocardial infarction, repeated urgent revascularization", 
                "measure": "Major adverse cardiovascular events", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Guangdong General Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Peking University First Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Chinese PLA General Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Guangdong General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}